Skip to main
AKTS

AKTS Stock Forecast & Price Target

AKTS Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 71%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aktis Oncology is a promising company with a strong focus on developing targeted radiopharmaceuticals for solid tumor cancers, particularly through its AKY-1189 and AKY-2519 pipeline products. With recent acquisitions and positive trial results for its drugs, the company is poised for success in the growing market for radiopharmaceutical treatments. The company's strong focus on targeting specific proteins found in various cancers sets it apart from other competitors in the space.

Bears say

Aktis Oncology is facing intense competition and has a CEO with limited industry experience, as well as a COO who has only been in her position since 2022. In addition, the company's pipeline products are still in the early stages of development, with no current revenues and limited data to support their efficacy. With a highly competitive landscape and lack of financial stability, Aktis Oncology's stock is likely to underperform in the short-term.

AKTS has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 71% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aktis Oncology Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aktis Oncology Inc (AKTS) Forecast

Analysts have given AKTS a Buy based on their latest research and market trends.

According to 7 analysts, AKTS has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aktis Oncology Inc (AKTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.